PMID- 34462967
OWN - NLM
STAT- MEDLINE
DCOM- 20211103
LR  - 20211103
IS  - 1346-8138 (Electronic)
IS  - 0385-2407 (Linking)
VI  - 48
IP  - 11
DP  - 2021 Nov
TI  - Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis 
      applications.
PG  - 1631-1639
LID - 10.1111/1346-8138.16116 [doi]
AB  - Janus kinase (JAK) inhibitors are emerging treatments for atopic dermatitis (AD). 
      Due to this novel role as a therapeutic option for patients with AD, we aimed to 
      review current evidence on the pathophysiology and the safety and adverse effects 
      (AEs) of oral JAK inhibitors for the treatment of AD utilizing the key terms 
      atopic dermatitis, JAK inhibitors, and adverse effect or event. Our study 
      indicated that oral JAK inhibitors have a moderate safety profile for use in AD 
      in several reviews and phase II or III clinical trials. Headaches, nausea, and 
      nasopharyngitis are the most commonly reported systemic AEs. Furthermore, acne, 
      herpes simplex, herpes zoster, and eczema herpeticum are the most commonly 
      recorded dermatological AEs. Current evidence indicates JAK inhibitors may also 
      have less association with some of the serious AEs, although there is potential 
      for increased risk of asthma, acute pancreatitis, neutropenia, and 
      thrombocytopenia. Whereas data remain limited for the long-term safety of JAK 
      inhibitor use in patients with AD, many ongoing clinical trials have promising 
      preliminary results.
CI  - (c) 2021 Japanese Dermatological Association.
FAU - Chang, Po-Hsiung
AU  - Chang PH
AUID- ORCID: 0000-0003-1561-7786
AD  - School of Medicine, Taipei Medical University, Taipei City, Taiwan.
AD  - Department of Pediatrics, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
FAU - Huang, Sheng-Fen
AU  - Huang SF
AD  - Department of Education and Learning Technology, National Tsing Hua University, 
      Hsinchu, Taiwan.
AD  - Graduate Institute of Medical Education & Bioethics, National Taiwan University 
      College of Medicine, Taipei City, Taiwan.
FAU - Chang, Po-Sheng
AU  - Chang PS
AD  - Department of Pediatrics, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
AD  - Division of Pediatric Gastroenterology, Department of Pediatrics, Far-Eastern 
      Memorial Hospital, New Taipei City, Taiwan.
FAU - Yu, Yu
AU  - Yu Y
AUID- ORCID: 0000-0002-8341-5994
AD  - Department of Dermatology, Cathay General Hospital, Taipei City, Taiwan.
AD  - Department of Dermatology, Sijhih Cathay General Hospital, New Taipei City, 
      Taiwan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210830
PL  - England
TA  - J Dermatol
JT  - The Journal of dermatology
JID - 7600545
RN  - 0 (Janus Kinase Inhibitors)
RN  - EC 2.7.10.2 (Janus Kinase 1)
SB  - IM
MH  - Acute Disease
MH  - *Dermatitis, Atopic/drug therapy
MH  - *Eczema
MH  - Humans
MH  - Janus Kinase 1
MH  - *Janus Kinase Inhibitors/adverse effects
MH  - *Pancreatitis
OTO - NOTNLM
OT  - Janus kinase inhibitor
OT  - adverse effect
OT  - atopic dermatitis
OT  - infection
OT  - malignancy
OT  - randomized control trial
OT  - systemic review
OT  - thromboembolism
EDAT- 2021/09/01 06:00
MHDA- 2021/11/04 06:00
CRDT- 2021/08/31 06:52
PHST- 2021/07/28 00:00 [revised]
PHST- 2021/06/15 00:00 [received]
PHST- 2021/07/31 00:00 [accepted]
PHST- 2021/09/01 06:00 [pubmed]
PHST- 2021/11/04 06:00 [medline]
PHST- 2021/08/31 06:52 [entrez]
AID - 10.1111/1346-8138.16116 [doi]
PST - ppublish
SO  - J Dermatol. 2021 Nov;48(11):1631-1639. doi: 10.1111/1346-8138.16116. Epub 2021 
      Aug 30.